Multikinase activity of fibroblast growth factor receptor (FGFR) inhibitors SU5402, PD173074, AZD1480, AZD4547 and BGJ398 compromises the use of small chemicals targeting FGFR catalytic activity for therapy of short stature syndromes

Logo poskytovatele
Logo poskytovatele

Varování

Publikace nespadá pod Ekonomicko-správní fakultu, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.
Autoři

GUDERNOVÁ Iva VESELA Iva BÁLEK Lukáš BUCHTOVÁ marcela DOSEDELOVA Hana KUNOVÁ Michaela PIVNIČKA Jakub JELÍNKOVÁ Iva ROUBALOVA Lucie KOZUBÍK Alois KREJČÍ Pavel

Rok publikování 2016
Druh Článek v odborném periodiku
Časopis / Zdroj Human Molecular Genetics
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
Doi http://dx.doi.org/10.1093/hmg/ddv441
Obor Genetika a molekulární biologie
Klíčová slova TYROSINE KINASE DOMAIN; ERK MAP KINASE; SELECTIVE INHIBITOR; CHONDROCYTE DIFFERENTIATION
Popis Activating mutations in the FGFR3 cause the most common genetic form of human dwarfism, achondroplasia. Small chemical inhibitors of FGFR tyrosine kinase activity (TKI) are considered to be viable option for treating achondroplasia but little experimental evidence supports this claim. We evaluated five FGFR TKIs (SU5402, PD173074, AZD1480, AZD4547 and BGJ398) for their activity against FGFR signaling in chondrocytes. All five TKIs strongly inhibited FGFR activation in cultured chondrocytes and limb rudiment cultures, completely relieving FGFR-mediated inhibition of chondrocyte proliferation and maturation. In contrast, TKI treatment of newborn mice did not improve skeletal growth and had lethal toxic effects on the liver, lungs and kidneys. In cell-free kinase assays as well as in vitro and in vivo cell assays, none of the tested TKIs demonstrated selectivity for FGFR3 over three other FGFR tyrosine kinases. In addition, the TKIs exhibited significant off-target activity when screened against a panel of 14 unrelated tyrosine kinases. This was most extensive in SU5402 and AZD1480, which inhibited DDR2, IGF1R, FLT3, TRKA, FLT4, ABL and JAK3 with efficiencies similar to or greater than those for FGFR. Low target specificity and toxicity of FGFR TKIs thus compromises their use for treatment of achondroplasia. Conceptually different avenues of therapeutic FGFR3 targeting should be investigated.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.